[
1. Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010. Erratum in: J Am Coll Cardiol. 2021 Apr 20;77(15):1958-1959. PMID: 33309175; PMCID: PMC7755038.
]Search in Google Scholar
[
2. Tamargo J, Rosano G, Walther T, et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother. 2017 Jul 1;3(3):163-182. doi: 10.1093/ehjcvp/pvw042. PMID: 28329228.10.1093/ehjcvp/pvw04228329228
]Search in Google Scholar
[
3. Bots SH, Groepenhoff F, Eikendal ALM, Tannenbaum C, Rochon PA, Regitz-Zagrosek V, Miller VM, Day D, Asselbergs FW, den Ruijter HM. Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women: A Systematic Review of the Literature. JACC Heart Fail. 2019 Mar;7(3):258-266. doi: 10.1016/j. jchf.2019.01.009. PMID: 30819382.
]Search in Google Scholar
[
4. Rosano GM, Lewis B, Agewall S, et al. Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC. Eur Heart J. 2015 Oct 21;36(40):2677-80. doi: 10.1093/eurheartj/ehv161. Epub 2015 May 6. PMID: 25948737.10.1093/eurheartj/ehv16125948737
]Search in Google Scholar
[
5. Stramba-Badiale M, Fox KM, Priori SG, et al. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J. 2006 Apr;27(8):994-1005. doi: 10.1093/eurheartj/ehi819. Epub 2006 Mar 7. PMID: 16522654.10.1093/eurheartj/ehi81916522654
]Search in Google Scholar
[
6. Maas AH, van der Schouw YT, Regitz-Zagrosek V, et al. Red alert for women’s heart: the urgent need for more research and knowledge on cardiovascular disease in women: proceedings of the workshop held in Brussels on gender differences in cardiovascular disease, 29 September 2010. Eur Heart J. 2011 Jun;32(11):1362-8. doi: 10.1093/eurheartj/ehr048. Epub 2011 Mar 15. PMID: 21406440.10.1093/eurheartj/ehr04821406440
]Search in Google Scholar
[
7. Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe—epidemiological update 2015. Eur Heart J. 2015 Oct 21;36(40):2696-705. doi: 10.1093/eurheartj/ehv428. Epub 2015 Aug 25. PMID: 26306399.10.1093/eurheartj/ehv42826306399
]Search in Google Scholar
[
8. Movsisyan NK, Vinciguerra M, Medina-Inojosa JR, Lopez-Jimenez F. Cardiovascular Diseases in Central and Eastern Europe: A Call for More Surveillance and Evidence-Based Health Promotion. Ann Glob Health. 2020 Feb 26;86(1):21. doi: 10.5334/aogh.2713. PMID: 32166066; PMCID: PMC7059421.10.5334/aogh.2713705942132166066
]Search in Google Scholar
[
9. Lee JH, Ryu HM, Bae MH, Kwon YS, Lee JH, Park Y, Heo JH, Lee YS, Yang DH, Park HS, Cho Y, Chae SC, Kim YN, Jun JE, Park WH. Prognosis and natural history of drug-related bradycardia. Korean Circ J. 2009 Sep;39(9):367-71. doi: 10.4070/kcj.2009.39.9.367. Epub 2009 Sep 30. PMID: 19949620; PMCID: PMC2771830.10.4070/kcj.2009.39.9.367277183019949620
]Search in Google Scholar
[
10. Vogler J, Breithardt G, Eckardt L. Bradyarrhythmias and conduction blocks. Rev Esp Cardiol (Engl Ed). 2012 Jul;65(7):656-67. English, Spanish. doi: 10.1016/j. recesp. 2012.01.025. Epub 2012 May 23. PMID: 22627074.
]Search in Google Scholar
[
11. Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol. 2001;2(6):349-51. doi: 10.2165/00128071-200102060-00001. PMID: 11770389.10.2165/00128071-200102060-0000111770389
]Search in Google Scholar
[
12. Deneer VH, van Hemel NM. Is antiarrhythmic treatment in the elderly different? a review of the specific changes. Drugs Aging. 2011 Aug 1;28(8):617-33. doi: 10.2165/11591680-000000000-00000. PMID: 21812498.10.2165/11591680-000000000-0000021812498
]Search in Google Scholar
[
13. Brenes-Salazar JA, Alshawabkeh L, Schmader KE, Hanlon JT, Forman DE. Clinical pharmacology relevant to older adults with cardiovascular disease. J Geriatr Cardiol. 2015 May;12(3):192-5. doi: 10.11909/j.issn.1671-5411.2015.03.018. PMID: 26089839; PMCID: PMC4460158.
]Search in Google Scholar
[
14. Marcum ZA, Amuan ME, Hanlon JT, et al. Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans. J Am Geriatr Soc. 2012 Jan;60(1):34-41. doi: 10.1111/j.1532-5415.2011. 03772.x. Epub 2011 Dec 8. PMID: 22150441; PMCID: PMC3258324.10.1111/j.1532-5415.2011.03772.x325832422150441
]Search in Google Scholar
[
15. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation. 2011 Nov 8;124(19):2145-54. doi: 10.1161/CIRCULATIONAHA. 110.968792. PMID: 22064958; PMCID: PMC3362050.
]Search in Google Scholar
[
16. Hammerman H, Kapeliovich M. Drug-related cardiac iatrogenic illness as the cause for admission to the intensive cardiac care unit. Isr Med Assoc J. 2000 Aug;2(8):577-9. PMID: 10979347.
]Search in Google Scholar
[
17. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Aug 27:ehab368. doi: 10.1093/eurheartj/ehab368. Epub ahead of print. PMID: 34447992.10.1093/eurheartj/ehab368
]Search in Google Scholar
[
18. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail. 2017 Aug;23(8):628-651. doi: 10.1016/j.cardfail. 2017.04.014. Epub 2017 Apr 28. PMID: 28461259.
]Search in Google Scholar
[
19. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612. Erratum in: Eur Heart J. 2021 Feb 1;42(5):507. Erratum in: Eur Heart J. 2021 Feb 1;42(5):546-547. Erratum in: Eur Heart J. 2021 Sep 14; PMID: 32860505.
]Search in Google Scholar
[
20. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179-84. doi: 10.1159/000339789. Epub 2012 Aug 7. PMID: 22890468.10.1159/000339789
]Search in Google Scholar
[
21. Turakhia MP, Blankestijn PJ, Carrero JJ, et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J. 2018 Jun 21;39(24):2314-2325. doi: 10.1093/eurheartj/ehy060. PMID: 29522134; PMCID: PMC6012907.10.1093/eurheartj/ehy060
]Search in Google Scholar
[
22. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol. 2003 Mar 20;91(6A):39D-44D. doi: 10.1016/s0002-9149(02)03378-7. PMID: 12670641.10.1016/S0002-9149(02)03378-7
]Search in Google Scholar
[
23. Antonelli D, Atar S, Freedberg NA, Rosenfeld T. Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions. Isr Med Assoc J. 2005 Mar;7(3):163-5. PMID: 15792261.
]Search in Google Scholar
[
24. EUGenMed Cardiovascular Clinical Study Group, Regitz-Zagrosek V, Oertelt-Prigione S, Prescott E, et al. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur Heart J. 2016 Jan 1;37(1):24-34. doi: 10.1093/eurheartj /ehv598. Epub 2015 Nov 3. PMID: 26530104.
]Search in Google Scholar
[
25. Linde C, Bongiorni MG, Birgersdotter-Green U, et al. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. Europace. 2018 Oct 1;20(10):1565-1565ao. doi: 10.1093/europace/euy067. PMID: 29961863.10.1093/europace/euy06729961863
]Search in Google Scholar
[
26. Roten L, Rimoldi SF, Schwick N, et al. Gender differences in patients referred for atrial fibrillation management to a tertiary center. Pacing Clin Electrophysiol. 2009 May;32(5):622-6. doi: 10.1111/j.1540-8159.2009.02335.x. PMID: 19422583.10.1111/j.1540-8159.2009.02335.x19422583
]Search in Google Scholar
[
27. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005 Feb;26(3):215-25. doi: 10.1093/eurheartj/ehi115. Epub 2005 Jan 9. PMID: 15642700.10.1093/eurheartj/ehi11515642700
]Search in Google Scholar
[
28. Lu HT, Kam J, Nordin RB, Khelae SK, Wang JM, Choy CN, Lee CY. Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study. J Geriatr Cardiol. 2016 Sep;13(9):749-759. doi: 10.11909/j.issn.1671-5411.2016.09.009. PMID: 27899939.
]Search in Google Scholar
[
29. Ko DT, Hebert PR, Coffey CS, et al. Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med. 2004 Jul 12;164(13):1389-94. doi: 10.1001/archinte.164.13.1389. PMID: 15249347.10.1001/archinte.164.13.138915249347
]Search in Google Scholar
[
30. Bots SH, den Ruijter HM. Recommended Heart Failure Medications and Adverse Drug Reactions in Women. Circulation. 2019 Mar 19;139(12):1469-1471. doi: 10.1161/CIRCULATIONAHA.118.037585. PMID: 30883224.10.1161/CIRCULATIONAHA.118.03758530883224
]Search in Google Scholar
[
31. Wehling M. Multimorbidity and polypharmacy: which betablocker to use in relation to the pharmacokinetic profile and interaction potential. Arzneimittelforschung. 2010;60(2):57-63. doi: 10.1055/s-0031-1296249. PMID: 20329652.10.1055/s-0031-129624920329652
]Search in Google Scholar
[
32. Valodara AM, Sr KJ. Sexual Dimorphism in Drug Metabolism and Pharmacokinetics. Curr Drug Metab. 2019;20(14):1154-1166. doi: 10.2174/1389200 2206661 91021094906. PMID: 31631817.
]Search in Google Scholar
[
33. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002 Oct 31;347(18):1403-11. doi: 10.1056/NEJMoa021266. PMID: 12409542.10.1056/NEJMoa02126612409542
]Search in Google Scholar
[
34. Whitley H, Lindsey W. Sex-based differences in drug activity. Am Fam Physician. 2009 Dec 1;80(11):1254-8. PMID: 19961138.
]Search in Google Scholar
